Irland - engelska - HPRA (Health Products Regulatory Authority)

bayer limited - gadopentetate dimeglumine - solution for injection - 469 micromol - paramagnetic contrast media

Kenya - engelska - Pharmacy and Poisons Board

bayer pharma ag bayer pharma ag 13342 berlin germany - gadopentetate dimeglumine - solution for injection - each ml contains 0.5 mmol gadopentetate… - contrast media - magnetic resonance imaging:

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) - solution for injection - 469 mg/ml - active: meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) excipient: meglumine pentetic acid water for injection

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) - solution for injection - 469 mg/ml - active: meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) excipient: meglumine pentetic acid water for injection - for diagnostic use by intravenous administration only. cranial and spinal magnetic resonance imaging (mri) in particular for the demonstration of tumours and for further differential-diagnostic clarification in suspected meningioma, (acoustic) neurinoma, invasive tumours (e.g. glioma) and metastases; for the demonstration of small and/or isointense tumours; in suspected recurrence after surgery or radiotherapy; for the differentiated demonstration of rare neoplasms such as haemangioblastomas, ependymomas and small pituitary adenomas; for improved determination of the spread of tumours not of cerebral origin. additionally in spinal mri: differentiation of intra- and extramedullary tumours; demonstration of solid tumour areas in known syrinx; determination of intramedullary tumour spread. whole body mri including the facial skull, the neck region, the thoracic and abdominal space, the female breast, the pelvis and the active and passive locomotive apparatus and imaging of vessels throughout the body. in particular, magnevist permits diagnostic information: · for the demonstration or exclusion of tumours, inflammation and vascular lesions; · for determination of the spread and demarcation of these lesions; · for the differentiation of the internal structure of lesions; · for assessment of the circulatory situation of normal and pathologically changed tissues; · for the differentiation of tumour and scar tissue after therapy; · for the recognition of recurrent prolapse of a disk after surgery. · for the semi-quantitative evaluation of the renal function combined with anatomical organ diagnosis.

Irland - engelska - HPRA (Health Products Regulatory Authority)

agfa healthcare imaging agents gmbh - gadopentetate dimeglumine - solution for injection - 0.5 mmol/ml

Irland - engelska - HPRA (Health Products Regulatory Authority)

sanochemia pharmazeutika ag - gadopentetate dimeglumine - solution for injection - 500 micromol

Kanada - engelska - Health Canada

bayer inc - gadopentetate dimeglumine - solution - 469mg - gadopentetate dimeglumine 469mg - other diagnostic agents

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - meglumine gadopentetate - solution for injection - .5mmol/1ml

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - meglumine gadopentetate - solution for injection - .5mmol/1ml

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - meglumine gadopentetate - solution for injection - .5mmol/1ml